BJH - volume 11, issue Abstract Book BHS, february 2020
E. Linskens , S. Van Landeghem , K. Vandepoele PhD, K. Maes , I. Moors MD, J. Van Dorpe , C. Bonroy , K. Devreese , J. Philippé MD, PhD, B. Denys PharmD
BJH - volume 11, issue Abstract Book BHS, february 2020
E. De Backer , P. Vlummens MD, R. Callens , I. Moors MD
BJH - volume 11, issue Abstract Book BHS, february 2020
E. Janssens , J. Van Dorpe , V. Van Hende MD, I. Moors MD, P. Vlummens MD, C. De Vriendt
BJH - volume 11, issue Abstract Book BHS, february 2020
S. Bonte , S. Van Gassen , A. Couckuyt , V. Janda , I. Moors MD, A. Delie , S. Kennes , J. Philippé MD, PhD, Y. Saeys , T. Kerre MD, PhD
BJH - volume 9, issue 7, december 2018
A. Delie , T. Kerre MD, PhD, I. Moors MD
Since several years, it has become clear that intermediate-risk acute myeloid leukaemia patients in an acceptable clinical condition can benefit from allogeneic stem cell transplantation thanks to the improvement in relapse free survival. This study retrospectively analysed the outcome of all intermediate-risk acute myeloid leukaemia patients treated with intensive chemotherapy at the Ghent University Hospital between 01-01-2013 and 30-04-2017 in an effort to determine the impact of a new in-hospital treatment guideline adopted in April 2015. This guideline recommends all intermediate-risk acute myeloid leukaemia patients who are fit for intensive therapy to proceed to allogeneic stem cell transplantation in first complete remission. Unfortunately, we could not demonstrate an improvement in the relapse free survival after implementation of the treatment guideline. Nevertheless, exploratory analysis of the entire group suggests a survival benefit from allogeneic stem cell transplantation, with significantly improved relapse free survival and a trend towards a better overall survival.
(BELG J HEMATOL 2018;9(7):285–9)
Read moreBJH - volume 9, issue 6, november 2018
K. Imaeva , I. Moors MD, J. Van Dorpe , S. Verbeke , B. Denys PharmD
Blastic plasmacytoid dendritic cell neoplasm is a highly aggressive myeloid neoplasm with a high rate of central nervous system recurrence. We present a case to illustrate central nervous system involvement and possible treatment options.
(BELG J HEMATOL 2018;9(6):237–41)
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
M. Hofmans MD, A. Delie , K. Vandepoele PhD, N. Van Roy PhD, J. Van der Meulen , J. Philippé MD, PhD, I. Moors MD
Top
